The US Food and Drug Administration (FDA) has approved Amneal Pharmaceuticals’ cyclosporine ophthalmic emulsion 0.05%, which is is the generic equivalent of RESTASIS 0.05%, a registered trademark of ...

Health Canada approved Eydenzelt, a biosimilar of Eylea, for multiple ophthalmic indications, based on comprehensive evidence including a phase 3 trial. The phase 3 trial demonstrated Eydenzelt's ...